Introduction
Recent findings from the ICMR AMR Surveillance Network reveal an alarming surge in drug-resistant pathogens such as Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli not only in tertiary ICUs but also across smaller secondary-care hospitals. As first-line and last-resort antibiotics lose efficacy, routine clinical infections and neonatal sepsis threaten to reverse decades of public health gains, making AMR a silent epidemic.
Why Resistance Is Reaching Smaller Hospitals and Drivers Behind
- Over-the-Counter Dispensing & Self-Medication: Weak enforcement of Schedule H and H1 rules under the Drugs and Cosmetics Act allows widespread non-prescription sale of broad-spectrum antibiotics. Example: Schedule H1 violation.
- Irrational Prescribing & Diagnostic Deficits in Smaller Hospitals: Absence of rapid microbiological culture facilities in district and private nursing homes forces empirical, prolonged broad-spectrum antibiotic usage. Example: Empirical broad-spectrum prescribing.
- Acute Vulnerability of Newborns & Maternal Wards: High resistance to ampicillin and cephalosporins drives fatal neonatal sepsis and prolonged ICU stays, inflating catastrophic out-of-pocket expenditure. Example: Neonatal sepsis mortality.
- One Health Spillovers from Poultry & Pharmaceutical Effluents: Unregulated antibiotic use as growth promoters in livestock and untreated pharmaceutical manufacturing discharge contaminate soil and water ecosystems. Example: Livestock antibiotic runoff.
Neonatal and Socio-Economic Risks
- Leading Pathogen: Klebsiella pneumoniae is the leading bacterium identified in newborn bloodstream infections in the ICMR report; nationwide NICU resistance data are still being analysed.
- High Mortality: A prospective study across five Indian district hospitals found a 36.6% case-fatality rate among culture-positive neonatal sepsis cases, with 75–88% of several major Gram-negative isolates multidrug-resistant.
- Financial Burden: When first-line drugs fail, patients need costlier reserve antibiotics, longer hospitalisation and intensive care. This increases out-of-pocket spending and deepens inequity, particularly for rural families dependent on secondary hospitals. AMR therefore threatens the constitutional promise of health and dignity under Article 21.
India’s One Health & AMR Stewardship Model for Regulatory Reforms
- Antimicrobial Stewardship Programs (AMSP): Institutionalizing ICMR’s AMSP guidelines across secondary hospitals ensures de-escalation from reserve drugs once culture reports arrive. Example: ICMR AMSP audits.
- WHO AWaRe Classification & Red-Line Campaign: Restricting “Watch” and “Reserve” antibiotics alongside public awareness via the Red-Line Campaign curbs inappropriate community consumption. Example: Red-Line packaging.
- National Action Plan on AMR (NAP-AMR 2.0): Synchronizing human health, animal husbandry, and environmental ministries under a One Health framework addresses cross-sectoral resistance pathways. Example: NAP-AMR 2.0 convergence.
Way Forward
- Decentralize Rapid Microbiology & Point-of-Care Diagnostics: Equip district hospitals and smaller clinics under the PM-ABHIM scheme with affordable rapid diagnostic kits to replace guesswork prescribing. Example: PM-ABHIM lab strengthening.
- Enforce Digital Prescription Audits & Schedule H1 Tracking: Mandate e-prescriptions and digitized pharmacy registries for Watch/Reserve antibiotics to curb over-the-counter sales. Example: Digital pharmacy tracking.
- Strengthen Hospital Infection Prevention & Control (IPC): Enforce strict hand hygiene, sterilization protocols, and antibiotic stewardship committees as mandatory conditions for NABH and AB-PMJAY empanelment. Example: PM-JAY quality linkage.
- Regulate Veterinary Use & Pharmaceutical Effluents: Strictly enforce the ban on colistin in animal feed and implement zero-liquid-discharge standards for bulk-drug manufacturing clusters. Example: Colistin feed ban.
Conclusion
Preserving antibiotic efficacy is foundational to safeguarding the constitutional right to health under Article 21. Integrating decentralized diagnostic capacity, strict pharmacy regulation, and One Health stewardship will protect vulnerable patients and secure resilient healthcare delivery.

